HANGZHOU, China–December 4, 2024 – HighField Biopharmaceuticals, a clinical stage company using lipid-based therapeutics to treat cancer, diabetes and other diseases, announced today that the Center for Drug Evaluation of China’s National Medical Products Administration has granted clearance of the company’s Investigational New Drug (IND) application to begin a clinical trial of HF50 in patients with advanced solid tumor cancers. 

HANGZHOU, China, September 12, 2024 – The recombinant humanized anti-EGFR-CD3 enzyme-controlled bispecific antibody (hereinafter referred to as CMDE005), developed by Centrymed based on its proprietary dual-antibody platform, proBiTE, has been approved for clinical trials by the NMPA for the treatment of various EGFR-positive advanced solid tumors. As the pharmaceutical research collaborator for the IND application of the CMDE005 project, HJB congratulates the approval of this project for clinical trials.

HANGZHOU, China, January 26, 2024 – HJB is excited to announce a major breakthrough in its Highly Intensified Continuous Bioprocessing (HiCB) platform. Utilizing its proprietary ExcelPro CHO™ cell culture medium, the HiCB platform has reached an impressive productivity of 8 g/L-day in intensified continuous perfusion, more than 15X increase over conventional fed-batch processes with the same cell line.  

HANGZHOU, China, November 06, 2023 – HJB announced a new strategic partnership with Hangzhou Apextide Bio-pharmaceutical Technology Company Limited. This strategic partnership will pursue the marketing and promotion of the APIs and DP manufacturing of oligonucleotide.

Due to promising clinical development, a client solicited HJB's support to make significant process improvements to their early-stage manufacturing process in preparation for late-stage clinical development and eventual commercial launch.

HJB congratulates its partner BioneCure for receiving IND approval for BIO-106.

HJB congratulates its client on an approval of CMC process change supplemental application filed to  NMPA in support of a late phase clinical trial in China.

HJB Congratulates its partner Kanova Biopharma for receiving IND approval from U.S.FDA for XKH001, a humanized monoclonal antibody for the treatment of autoimmune disease.